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ABSTRACT
Extended-spectrum b-lactamases (ESBLs) derived from the TEM-1 b-lactamase were ﬁrst identiﬁed in
the USA in outbreak strains of Klebsiella pneumoniae in the middle to late 1980s, together with the SHV-5
ESBL. The TEM-10, TEM-12 and TEM-26 enzymes have remained in US hospitals, but have been joined
by other ESBLs that are variants of the SHV-1 broad-spectrum b-lactamase. In the most recent surveys
from hospitals in the eastern part of the USA, the most prominent ESBLs have been the SHV-7 and SHV-
12 enzymes. In Canada, a wider variety of ESBLs has been identiﬁed, with multiple members of the
TEM, SHV and CTX-M classes being represented in surveillance isolates. SHV-type and CTX-M ESBLs
have appeared in many Canadian isolates, with an outbreak of CTX-M-14-related enzymes from
Calgary, but limited TEM-derived ESBLs. Surprisingly, few CTX-M ESBLs have yet been reported in the
USA, in contrast to the rest of the world, where the CTX-M enzymes have become a predominant ESBL
family.
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BACKGROUND
When aminothiazole-containing third-generation
cephalosporins and monobactams were identiﬁed
in the late 1970s and early 1980s, a major criterion
for their development was a need for stability in
the presence of the troublesome TEM and SHV
b-lactamases that had emerged in the Enterobac-
teriaceae [1]. The broad-spectrum TEM-1, TEM-2
and SHV-1 enzymes, as well as the OXA-1
oxacillinase, had become the most commonly
identiﬁed plasmid-encoded enzymes in multiple
surveys of b-lactamase production worldwide [2].
Most importantly, they were capable of being
transferred among genera of Gram-negative bac-
teria, as demonstrated early in the history of the
TEM b-lactamase that was readily acquired by
gonococci, presumably from Escherichia coli [3,4].
As a result, widely used b-lactams became inef-
fective against many of the Enterobacteriaceae
that produced these enzymes.
The introduction of antibacterial agents such as
cefotaxime, ceftazidime and aztreonam was met
with high hopes that these drugs would control
the proliferation of b-lactamase-producing Gram-
negative pathogens, with the possible exceptions
of the AmpC cephalosporinase-producing pseu-
domonads and Enterobacteriaceae. In a somewhat
premature statement in 1981, C. W. Kunin stated
that these agents were ‘magniﬁcent examples of
good scientiﬁc thinking and good chemistry on
the part of the pharmaceutical manufacturers’, a
response typical of many in the infectious disease
community at the time [5]. Resistance to these
agents was predicted to emerge, most likely as a
result of hyperproduction of the chromosomal
AmpC-type cephalosporinase [6].
However, it was the plasmid-encoded enzymes
that proved to be more versatile in mutating to
confer resistance to these new agents. Transfer-
able cefotaxime resistance was ﬁrst reported from
Germany in 1983 [7], and this was followed by
large outbreaks of transferable cefotaxime or
ceftazidime resistance in France, beginning in
1985 [8–10]. The responsible enzymes, variants of
the common TEM and SHV b-lactamases with one
to four point mutations of single nucleotides in
the parent gene, were named ‘extended-spectrum
b-lactamases’ (ESBLs) because of their ability to
hydrolyse the extended-spectrum b-lactams,
including cephalosporins and monobactams [11].
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Early TEM b-lactamases
All the early North American ESBLs that were
identiﬁed were members of the TEM family, with
a number of variants that included the TEM-10,
TEM-12 and TEM-26 b-lactamases, as shown in
Table 1. The chronology outlining their identiﬁ-
cations demonstrates a wide geographical diver-
sity over a very short period.
In 1986, Bakken et al. submitted a paper
describing a ceftazidime-resistant E. coli isolate
from a patient who had received ceftazidime for
8 weeks; at that time, the authors did not believe
that the resistance was related to the apparent
TEM-1 b-lactamase in the strain [22]. The ﬁrst
report of a recognised ESBL in North America
was from Jacoby et al. from Boston, in February
1988 [23], and this was followed by a report from
Quinn et al. describing ceftazidime-resistant Kle-
bsiella pneumoniae isolates identiﬁed in mid-1988
from Chicago, and later shown to be TEM-10-
producers [13]. During this time-frame, the TEM-
26 b-lactamase had also emerged in January 1988,
in a paediatric oncology ward in Stanford CA,
where ceftazidime had been used as monotherapy
[18]. Curiously, in the New York Medical Center
of Queens in New York City, beginning in
October 1988, the same TEM-26 enzyme began
to cause one of the largest ESBL outbreaks that
has been recognised in the USA [19,24], 436
ceftazidime-resistant K. pneumoniae isolates being
identiﬁed over a period of 19 months. Reports
from the Boston area of three different TEM-
related ESBLs during that period were later also
identiﬁed as TEM-10, TEM-12 and TEM-26 ESBLs
[16,23,25]. Eventually, the putative TEM-1 b-lac-
tamase from the Bakken strain in 1986 was
demonstrated to be TEM-12, a single-amino-acid
variant of TEM-1 and the precursor to either
TEM-10 or TEM-26 [15].
It is not surprising that other related TEM
b-lactamases, such as TEM-28 and TEM-43
[20,21], were identiﬁed in the USA at later times.
As seen in Table 1, all these US TEM enzymes are
derived from TEM-1 rather than from its point
mutant TEM-2. All these variants contain a
substitution of either serine or histidine at posi-
tion 164, and also contain a lysine substitution at
either position 104 or position 240. Thus, one can
envision a series of point mutations occurring
within this family to give the set of TEM ESBLs
that emerged in the USA.
Most of the TEM ESBL enzymes appear in
K. pneumoniae, although E. coli has served as the
host organism for some ESBLs. When ESBLs are
produced in K. pneumoniae, multiple b-lactamases
are usually present, often including a parental
TEM-1 and an SHV enzyme, as well as the TEM
ESBL [19]. Occasionally, both TEM-12 and TEM-
10 have been identiﬁed in the same strain [17].
Early SHV b-lactamases
The emergence of SHV variants in North America
was less dramatic than observed with the TEM
ESBLs, with no major epidemics resulting from
the early appearance of these enzymes. The ﬁrst
SHV-related family member in the USA was the
OHIO-1 enzyme, which appeared in the mid-
1980s in the state of Ohio, with >90% amino-acid
Table 1. Amino-acid substitutions associated with TEM variants identiﬁed in the USA
TEM Location(s)
Date of ﬁrst
identiﬁcation
Amino-acid substitution at positiona
Reference104 164 182 240
1 Glu Arg Met Glu [12]
10 Boston, MA
Chicago, IL
1988 Glu Ser Met Lys [13,14]
12 Boston, MA
Chicago, IL
1988 Glu Ser Met Glu [15–17]
26 Boston, MA
New York City, NY
Stanford, CA
1988 Lys Ser Met Glu [16,18,19]
28 Los Angeles, CA 1992 Glu His Met Lys [20]
43 St Louis, MO 1992–1996 Lys His Thr Glu [21]
aBold type indicates a substitution leading to a difference from the TEM-1 amino-acid sequence.
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identity with SHV-1 [26–28]. However, OHIO-1
seemed to confer no long-term selective advan-
tage, and subsequently disappeared from the
community ﬂora (R. Bonomo, personal commu-
nication).
Other SHV ESBLs were identiﬁed later, in a
more random molecular order than the TEM
variants. SHV-5, originally sequenced in 1990
from a K. pneumoniae isolate from Chile, with two
amino-acid substitutions as compared to SHV-1,
was determined retrospectively to be present in
Albany, NY in isolates as early as 1993 [29]. SHV-
7, with four amino-acid substitutions as com-
pared to SHV-1 (Table 2), appeared in four highly
ceftazidime-resistant E. coli isolates in 1993, at the
same hospital in New York where TEM-26 had
emerged [30]. Interestingly, three of the elderly
patients who harboured these organisms had
entered the hospital from different nursing
homes, with no prior antibiotic usage. In the
meantime, in 1990, SHV-8, a single point mutant
of SHV-1, had appeared in a highly resistant
E. coli strain in a paediatric patient from Georgia,
who had been given multiple regimens of anti-
infective drugs, including both b-lactams and
non-b-lactams, but has not been reported subse-
quently [31]. SHV-29, with three point mutations,
was later identiﬁed in a K. pneumoniae strain from
North Carolina that also produced the KPC-1
serine carbapenemase [32]. Interestingly, the ﬁrst
KPC-2-producing strain, a Klebsiella oxytoca iso-
late, also harboured a new SHV variant, SHV-46,
with three amino-acid substitutions as compared
to SHV-1.
In contrast to the TEM family of enzymes, the
US SHV b-lactamases demonstrated greater var-
iability, with more mutable positions being rep-
resented in their repertoire. As seen in Table 2,
the six major SHV members in North American
collections had amino-acid substitutions at seven
positions, as compared to the ﬁve major TEM
enzymes with only four mutable positions repre-
sented. Four of the six SHV ESBLs contained
Gly238Ser and Glu240Lys substitutions; these are
the most frequently altered positions of this ESBL
group. SHV-8, with the Asp179Asn mutation, was
the only variant with a single point mutation, and
the only SHV ESBL in the USA with a point
mutation at this position.
RECENT SURVEYS
Epidemiological surveys in North America have
demonstrated strikingly different patterns of
ESBL production between the USA and Canada.
In the USA, large surveillance studies have been
conducted by the CDC for their ICARE (Intensive
Care Antimicrobial Resistance Epidemiology)
project and by the SENTRY and MYSTIC projects.
SENTRY isolates, primarily from 1997 and 1998,
demonstrated that US centres had a higher per-
centage of K. pneumoniae strains with an ESBL
phenotype than did Canadian centres (7.6% vs.
4.9%), whereas approximately equal percentages
of E. coli isolates had ESBL phenotypes (3.3% vs.
4.2% for the USA and Canada, respectively) [39].
In a more recent analysis of data from the
MYSTIC program in the USA, from 1999–2004
[40], ESBL production was monitored on a yearly
basis in E. coli and Klebsiella spp. In 1999, an ESBL
phenotype was detected but was not conﬁrmed in
5.1% and 7.2% of the E. coli and klebsiellae
Table 2. Amino-acid substitutions associated with SHV variants identiﬁed in the USA
SHV Location(s)
Date of ﬁrst
identiﬁcation
Amino-acid substitution at positiona
Reference8 35 43 179 195 238 240
1 Ile Leu Arg Asp Thr Gly Glu [33]
5b Albany, NY 1993b Ile Leu Arg Asp Thr Ser Lys [34]
7 New York City, NY 1993 Phe Leu Ser Asp Thr Ser Lys [30]
8 Georgia 1990 Ile Leu Arg Asn Thr Gly Glu [31]
12c St Louis, MO 1996 Ile Gln Arg Asp Thr Ser Lys [35]
29 North Carolina NDd Ile Gln Ser Asp Thr Ala Glu [32]
46 New York 1998 Ile Leu Arg Asp Asn Ser Lys [36]
aBold type indicates a substitution leading to a difference from the SHV-1 amino-acid sequence.
bOriginally identiﬁed from a 1987 Chilean isolate [37].
cOriginally identiﬁed in Switzerland in 1993–1995 [38].
dNo data. Reported in 2001.
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isolates, respectively. In 2000, ESBLs were con-
ﬁrmed in 3.1% of each of the sets of E. coli and
Klebsiella spp. isolates. Surprisingly, fewer than
1.5% of the E coli strains from 2001–2004 pro-
duced ESBLs, whereas a low level of ESBL
production (2.4–4.4%) was seen in Klebsiella spp.
over these 4 years, with these low results perhaps
being due to a selected set of sampling sites.
These observations were in contrast to at least a
50% increase in ESBL production to >10% in both
genera in European isolates collected over the
same time period [40]. This study is also in
contrast to a 63-site survey set up for ESBL
identiﬁcation, conducted in 2001–2002 by Moland
et al., at 42 intensive care unit and 21 non-
intensive care unit sites across the USA; in this
study, ESBL production was reported in 11.3%
and 2.6% of the K. pneumoniae and E. coli isolates,
respectively [41].
As seen in Table 3, various US surveys of ESBL
production have been conducted over the past
decade, outlining the families or variants of ESBL-
producing organisms. The major enzymes in the
1990s appeared to be a few TEM and SHV types
that have been present for many years in the USA
(Table 4). Recently, SHV enzymes have become
prominent, especially in the New York City area,
where TEM enzymes were initially the only
ESBLs, and remained the predominant ESBLs in
the late 1980s and early 1990s.
No CTX-M b-lactamases have been reported to
be associated with ESBL outbreaks in the USA, in
contrast to most of the rest of the world, where
this b-lactamase family has become the prominent
ESBL group. One report describing nine CTX-
M-producing isolates from ﬁve geographically
diverse US sites has appeared [50], but other
surveillance studies have not yet reported the
presence of this enzyme in large populations of
Enterobacteriaceae.
In Table 5, a set of surveillance data demon-
strates a different pattern of b-lactamase produc-
tion in Canada [51–54]. SHV ESBLs are prevalent
in Canadian samples, with very few TEM
ESBL-producing strains having been identiﬁed.
As seen from these studies, ESBL production is
sporadic, and represents a relatively small per-
centage of E. coli, K. pneumoniae and Salmonella
isolates. The one exception was the large
outbreak of CTX-M ESBLs from Calgary in
2000–2002, in which 168 patients from 20 towns
and villages were infected with organismsT
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producing CTX-M-14 and closely related CTX-M-
14-type ESBLs [54].
FUTURE OF ESBLs
At this time, the ESBL proﬁles differ considerably
between the USA and Canada. The early appear-
ances of SHV-5, SHV-7 and SHV-12 in the USA
have tended to predict the later prevalence of
these enzymes in North America in both coun-
tries. However, the early US outbreaks associated
with TEM-10 and TEM-26 seem to have abated,
perhaps due to the replacement of ceftazidime on
selected hospital formularies [55].
One of the more disconcerting factors that has
been recognised since the ﬁrst occurrence of
ESBLs in the Americas is the presence of multiple
b-lactamases in cephalosporin-resistant isolates.
Although early strains were reported to produce
two to four b-lactamases [19,30], a recent report of
at least eight enzymes in a single K. pneumoniae
isolate emphasises the ability of these organisms
to accumulate multiple resistance determinants
[56]. Not only was an SHV-12-like ESBL present
in this isolate, but a KPC serine carbapenemase
was also produced, together with an inhibitor-
resistant TEM-30-like b-lactamase, similar to the
proﬁle reported by Bradford et al. in 2004 [57].
Should strains like these proliferate, b-lactams
will no longer be appropriate ﬁrst-line therapeutic
options for empirical treatment of serious
infections.
Of all the observations concerning the ESBL
picture in the USA, the most curious is the
minimal appearance of CTX-M enzymes. The
CTX-M b-lactamases have become the predomi-
nant ESBL family in many parts of the world, but,
to date, have not been responsible for any
reported outbreaks in US hospitals. Prescribing
patterns and antibiotic usage are certainly factors
contributing to this pattern, but speciﬁc contrib-
utory differences between the US practices and
those in other parts of the world have not been
identiﬁed. It is currently not known whether this
trend of low CTX-M prevalence will continue, or
whether the enzymes that appeared in several US
hospitals in 2003 will eventually spread through-
out the USA, as they have done in many other
parts of the world. Their existence in Canada
suggests that it is only a matter of time before they
become a problem in the USA, where it is possible
that these enzymes are already co-produced withT
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other ESBLs, but have yet to be identiﬁed. As with
all b-lactamase developments, one can only pre-
dict that ESBLs will continue to plague us as long
as we use b-lactam antibiotics, which serve as
potent selecting agents.
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